

Prospective, Registry-Based Observational Cohort Study of Zavege pant Safety in Pregnancy

First published: 18/10/2024

Last updated: 12/06/2025

Study

Planned

Administrative details

EU PAS number

EUPAS1000000335

Study ID

1000000335

DARWIN EU® study

No

Study countries

United States

Study description

In March 2023, the US FDA approved zavegeptan (ZAVZPRET) for the acute treatment of migraine with or without aura in adults. Zavegeptan is the first CGRP receptor antagonist available to patients in nasal spray form. CGRP receptor antagonists represent the newest class of migraine treatments that reduce pain through interfering with CGRP-induced vasodilation and inflammation.

Migraine is common, especially among women, with a prevalence of 21% in US women and 10% in US men. Prevalence peaks in mid-life and women of reproductive age carry the greatest migraine burden. Migraine is associated with a higher risk of some adverse pregnancy outcomes including pre-eclampsia and gestational hypertension.

While no adverse developmental effects were observed in zavegeptan animal studies, there are limited data on the safety of zavegeptan use in pregnant individuals (ZAVZPRET label 2023). This study will address this gap in information on the safety of zavegeptan when used in pregnancy in terms of risk of maternal and/or infant outcomes. This will be a new, product-based registry that recruits pregnant women with migraine as well as pregnant women taking zavegeptan. This non-interventional study (NIS) is designated as a postauthorization safety study (PASS) and is a post-marketing commitment to the FDA.

Study status

Planned

Research institutions and networks

Institutions

Pfizer

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Pharmaceutical Product Development (PPD)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Andrea Leapley andrea.leapley@pfizer.com

Study contact

andrea.leapley@pfizer.com

Primary lead investigator

Monica Bertoia

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 17/06/2024

Actual: 17/06/2024

Study start date

Planned: 31/10/2024

Data analysis start date

Planned: 01/01/2025

Date of interim report, if expected

Planned: 30/06/2025

Date of final study report

Planned: 30/06/2038

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Pfizer 100%

Study protocol

[C5301026_ZAVEGEPANT PREGNANCY REGISTRY](#)

[PROTOCOL_V3.0_06SEP2024.pdf \(982.13 KB\)](#)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

C5301026

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Data collection methods:

Study design:

A registry-based, prospective observational cohort study

Main study objective:

1. To estimate the prevalence of MCM births (primary outcome) among pregnant individuals with migraine who are (1) exposed to zavegeptant (internal exposed cohort), and (2) unexposed to zavegeptant (internal comparator cohort).
2. To estimate the RR of MCM births in the exposed internal cohort versus the unexposed internal cohort.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name, other

Zavzpret

Study drug International non-proprietary name (INN) or common name

MIGLUSTAT

Anatomical Therapeutic Chemical (ATC) code

(A16AX06) miglustat

miglustat

Population studied

Short description of the study population

Pregnant individuals 15 to 50 years of age in the US, including individuals with migraine exposed to zavegeptant during pregnancy and individuals with migraine unexposed to zavegeptant during pregnancy.

Age groups

- Adults (18 to < 65 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)

Special population of interest

Pregnant women

Estimated number of subjects

728

Study design details

Setting

The 2 internal study cohorts will be derived from eligible individuals enrolled in the pregnancy registry. The virtual registry coordinating center (VRCC) will coordinate enrollment and data collection for the internal study cohorts (details provided in Protocol Section 9.4). The external nonmigraine cohort will include individuals identified within the claims database. All 3 cohorts of pregnant

individuals will be identified in the US during the study period.

Comparators

Internal comparator cohort

All remaining eligible individuals who are not exposed to zavegeptan during pregnancy will be included in the comparator cohort. This cohort will include individuals who are and are not exposed to migraine treatments.

External nonmigraine cohort

An external cohort of pregnant individuals without migraine will provide context to the main study results by estimating background rates of the study outcomes among pregnant individuals. This cohort will be identified within the ORD, a US-based health insurance claims database. See Protocol Section 9.4.5 for details about the ORD. Methods for identifying and characterizing the external nonmigraine cohort are described in detail in Annex 1, the draft protocol “Observational Cohort Study of Zavegeptan Safety in Pregnancy Within a US Claims Database.”

Outcomes

MCM is the primary outcome of interest and all other outcomes are secondary. All outcome data are collected via HCPs. Protocol Table 1 presents the definitions of the outcomes of interest.

Data analysis plan

Detailed methodology for summary and statistical analyses of data collected in this study will be documented in a statistical analysis plan (SAP), which will be dated, filed and maintained by the Sponsor. The SAP may modify the plans outlined in the protocol; any major modifications of primary endpoint definitions or their analyses would be reflected in a protocol amendment.

Documents

Study report

[c5301026-interim1-report-body.pdf](#) (779.8 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

Primary data collection

Data sources (types)

[Pregnancy registry](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown